All transplant centers participating in the CIBMTR must submit a Pre-TED (2400) Form for each allogeneic (related or unrelated) hematopoietic cell transplant (HCT). The Pre-TED is a requirement of the SCTOD for all United States transplant centers when either the stem cell donation or the transplant occurs within the United States. For more information regarding the SCTOD, see General Instructions, Stem Cell Therapeutics Outcomes Database.

Although data regarding recipients receiving autologous HCTs are not required to be submitted as part of the C.W. Bill Young Transplant Program, the CIBMTR is highly committed to collecting data on these recipients for research studies. Centers choosing to report autologous data to the CIBMTR must report on all autologous transplants performed at their center. For more information regarding data reporting for autologous HCT, review HCT in the Data Management Guide.

The Pre-TED may be submitted to the CIBMTR up to two weeks prior to the start of the recipient’s preparative regimen (see Helpful Hint below).

Figure 1. Disabled Edit Form Icon

Figure 2. Hovered Text, Consent Not Yet Reported

For recipients receiving a subsequent HCT:
Transplant centers must submit a Pre-TED for all subsequent HCTs; this includes recipients assigned to the TED Forms and the Comprehensive Report Forms by the form selection algorithm.

For the majority of subsequent HCTs, the recipient will remain on the original follow-up form track assigned by the form selection algorithm. For more information regarding center type and the form selection algorithm, see Section 1 in the Center Reference Guide. A recipient may need to change tracks if enrolled on a study that requires comprehensive forms.

For recipients of multiple transplants, transplant centers are not granted access to the new Pre-TED Form in FormsNet3 until the Post-TED (Form 2450) or Post-Infusion Data Form (Form 2100) from the previous transplant has been completed.

Transplant centers can use the FormsNet3 application to determine if a Pre-TED is due by either: 1) accessing the Forms Due Report, or 2) entering the recipient’s unique ID (CRID) in the Patient Forms Due field.

Links to Sections of the Form:
Q1 – 21: Recipient Information
Q22 – 41: Hematopoietic Cellular Transplant (HCT) and Cellular Therapy
Q42 – 80: Donor Information
Q81 – 86: Clinical Status of Recipient Prior to the Preparative Regimen
Q87 – 119: Comorbid Conditions
Q120 – 134: Pre-HCT Preparative Regimen
Q135 – 139: Additional Drugs Given in the Peri-Transplant Period
Q140 – 142: GVHD Prophylaxis
Q143 – 145: Post-HCT Disease Therapy Planned as of Day 0
Q146: Prior Exposure: Potential Study Eligibility
Q147 – 157: COVID-19 (SARS-CoV-2) Impact on Hematopoietic Cell Transplantation

Manual Updates:
Sections of the Forms Instruction Manual are frequently updated. The most recent updates to the manual can be found below. For additional information, select the manual section and review the updated text.

If you need to reference the historical Manual Change History for this form, please click here or reference the retired manual section on the Retired Forms Manuals webpage.

Date Manual Section Add/Remove/Modify Description
10/20/2022 2400: Pre-TED Add Instructions for Q17 – 18 updated to include PedAL option: If the study sponsor is reported as USIDNET, COG, or PedAL continue with Subject ID.
10/20/2022 2400: Pre-TED Add Instructions for Q16 updated to include PedAL option: Indicate if the recipient is a registered participant with BMT-CTN, RCI-BMT, USIDNET, COG, PedAL and/or another clinical trial sponsor that uses CIBMTR forms to capture outcomes data.
10/18/2022 2400: Pre-TED Add Clarification added on how to answer Q135 – 139 when peri-transplant drugs were not given: If the recipient did not receive any of the drugs listed above, leave these questions blank and override the error as ‘verified correct.’
9/23/2022 2400: Pre-TED Modify Version 9 of the 2400: Pre-TED section of the Forms Instruction Manual released. Version 9 corresponds to revision 10 of the Form 2400.
Last modified: Oct 20, 2022

Need more help with this?
Don’t hesitate to contact us here.

Was this helpful?

Yes No
You indicated this topic was not helpful to you ...
Could you please leave a comment telling us why? Thank you!
Thanks for your feedback.